

<u>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</u>	
EV 323497533 US Express Mail Label Number	JUNE 24, 2003 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1625

ROBL ET AL.

Examiner: Evelyn Mei Huang

APPLICATION NO: DIVISION OF APPLICATION SERIAL NO.

10/007,407, FILED DECEMBER 4, 2001

FILED: HEREWITH

FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed concurrently with the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/007,407 filed December 4, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
\_\_\_\_\_  
Burton Rodney  
Attorney for Applicants  
Reg. No. 22,076

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4336

Date: June 24, 2003

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL600712890US  
Express Mail Label Number

June 6, 2001  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

APPLICATION NO: UNKNOWN

FILED: HEREWITH

FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed concurrently with the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
\_\_\_\_\_  
Burton Rodney

Attorney for Applicants  
Reg. No. 22,076

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4336

Date: June 6, 2001

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

ATTY. DO NO.

HX0115 N

APPLICATION NO.

APPLICANT

ROBL ET AL.

FILING DATE

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,906,624	3/6/90	Chacholowski et al			
	AB	4,925,852	5/15/90	Keeseler et al			
	AC	5,006,530	4/9/91	Angerbauer et al			
	AD	5,169,857	12/8/92	Angerbauer et al			
	AE	5,177,080	1/5/93	Angerbauer et al			
	AF	5,686,433	11/11/97	Robl			
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM	EP 0306929A2	3/15/89	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0307342A2	3/15/89	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 0325129A2	7/26/89	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	EP0325130A2	7/26/89	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Robl et al, J. Med. Chem., 34, 2804-2815, 1991.
AS	
AT	

## EXAMINER

## DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Burton Rodney

Type or print name

\_\_\_\_\_  
Signature

\_\_\_\_\_  
11/28/01  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

APPLICATION NO: 09/875,155

FILED: JUNE 6, 2001

FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


These references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

  
Burton Rodney  
Attorney for Applicants  
Reg. No. 22,076

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4336

Date: 11/18/01

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL596928075US  
Express Mail Label Number

12/4/01  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
ROBL ET AL.  
APPLICATION NO: UNKNOWN  
FILED: HEREWITH  
FOR: HMG-COA REDUCTASE INHIBITORS AND METHOD

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed concurrently with the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/875,515 filed June 6, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
Burton Rodney  
Attorney for Applicants  
Reg. No. 22,076  
(609) 252-4336

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
Date: December 4, 2001

(Use several sheets if necessary)

ATTY. DOC. NO.  
HX0115 NP  
APPLICATION NO.  
09/875,155  
APPLICANT  
ROBL ET AL.  
FILING DATE  
JUNE 6, 2001

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	5,753,675	5/19/98	Wattanasin, S.			
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	EP 0491226A	6/24/92	Europe			<input type="checkbox"/>	<input type="checkbox"/>
AN	EP 0444533A	9/11/97	Europe			<input type="checkbox"/>	<input type="checkbox"/>
AO	EP 0818197A	1/14/98	Europe			<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AR	
AS	
AT	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.